| Hutchins, Jacob |
NCT06143306: Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement |
|
|
| Recruiting | 4 | 110 | US | bupivacaine., Saline | University of Minnesota | Total Shoulder Arthroplasty | 10/26 | 05/27 | | |
| Not yet recruiting | 4 | 48 | NA | 0.5% bupivacaine, Saline | University of Minnesota | Esophagectomy, Pneumonectomy, Lobectomy | 01/27 | 04/27 | | |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
| Forman, Seth |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia |
|
|
| Completed | 3 | 400 | US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 11/23 | 11/23 | | |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 02/26 | 02/27 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities |
|
|
| Completed | 3 | 751 | US | Tirzepatide, LY3298176, Semaglutide | Eli Lilly and Company | Obesity, Overweight | 11/24 | 11/24 | | |
| Recruiting | 3 | 300 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Chronic Migraine | 07/25 | 03/26 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
| Recruiting | 3 | 325 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Episodic Migraine | 11/25 | 11/26 | | |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata |
|
|
| Active, not recruiting | 2/3 | 824 | Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company, Incyte Corporation | Alopecia Areata | 02/21 | 01/25 | | |
|
|
| Completed | 2 | 302 | Europe, Canada, US, RoW | Placebo Comparator, ASLAN004 | ASLAN Pharmaceuticals | Atopic Dermatitis | 06/23 | 09/23 | | |
| Completed | 2 | 30 | Canada, US | Daxdilimab, HZN-7734 | Amgen | Alopecia Areata | 08/23 | 01/24 | | |
NCT05080764: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults |
|
|
| Recruiting | 2 | 126 | US | 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Acne Vulgaris | 09/25 | 11/25 | | |
NCT06602219: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 220 | Canada, Japan, US | LY4100511, Placebo | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Plaque Psoriasis | 07/25 | 08/25 | | |
NCT06742281: A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults |
|
|
| Recruiting | 2 | 10016 | US | CVXGA (CVXGA50), COMIRNATY® | CyanVac LLC, Biomedical Advanced Research and Development Authority | COVID-19 | 06/26 | 06/27 | | |
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
| Goza, Amanda T |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
| Nelson, Candace |
NCT06143306: Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement |
|
|
| Recruiting | 4 | 110 | US | bupivacaine., Saline | University of Minnesota | Total Shoulder Arthroplasty | 10/26 | 05/27 | | |
| Recruiting | 4 | 50 | US | 3 methods intervention | University of Minnesota | Epidural Placement | 09/26 | 03/27 | | |
NCT06278987: Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture |
|
|
| Recruiting | 4 | 150 | US | PENG block and cryoablation, fascia iliaca compartment block | University of Minnesota | Hip Fractures | 10/26 | 10/27 | | |
NCT06023329: Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic Surgery |
|
|
| Recruiting | 4 | 36 | US | ropivacaine, Saline | University of Minnesota | Otolaryngologic Surgery | 04/25 | 04/25 | | |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
| Recruiting | N/A | 30 | US | Negative Connotation Langauge, Positive Connotation Language | University of Minnesota | Anesthesia | 12/25 | 12/25 | | |
| Berkowitz, Richard |
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia |
|
|
| Completed | 3 | 400 | US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 11/23 | 11/23 | | |
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery |
|
|
| Completed | 3 | 466 | Europe, US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 07/24 | 07/24 | | |
NCT04763759: Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections |
|
|
| Completed | 1 | 15 | US | TRL1068, a human monoclonal antibody | Trellis Bioscience LLC, University of California, Los Angeles, Biomedical Advanced Research and Development Authority, Wellcome Trust, Sinai Hospital of Baltimore, Gulfcoast Research Institute, Phoenix Clinical Research, University of Florida, University of Alabama at Birmingham, The Methodist Hospital Research Institute, University of Virginia, University of Southern California | Prosthetic Joint Infection | 03/24 | 03/24 | | |
